For toddlers allergic to peanuts, a tiny bit of protein therapy under the tongue could be the best approach
CHAPEL HILL, NC — A three-year clinical trial funded by the National Institutes of Health and Food Allergy Research and Education (FARE) has shown that the sublingual immunotherapy, or SLIT, is safe in peanut-allergic children ages 1 to 4, with a greater likelihood of desensitization and remission the earlier the treatment began.
Led by Edwin Kim, MD, associate professor of pediatrics at the UNC School of Medicine, this is the first randomized, controlled trial to investigate – in this young age group – the efficacy and feasibility of SLIT, which ...
















